Clinical trial · Observational
Arimidex Observational: Reason for and Effect of Change From Tamoxifen
Arimidex: Reason for and Effect of Change From Tamoxifen
NCT00246961CI-TRIAL-00000914ARRESTcompletedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The purpose of this study is to analyse the effect on quality of life after 3 months of treatment after changing adjuvant therapy from tamoxifen to Arimidex.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Breast Cancer | Malignant Breast Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (0)
Data not yet available
No intervention recorded.
Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Postmenopausal * Hormone sensitive breast cancer * Patient uses tamoxifen or has stopped taking tamoxifen less than 7 days ago Exclusion Criteria: * Visceral metastases * Patients with signs of progression at the moment of changing therapy * Patients who have used other endocrine treatments for breast cancer besides tamoxifen
References
Publications (0)
Data not yet available
No reference posted for this study.